The regulation of MDM2 oncogene and its impact on human cancers

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 3, 2014, Pages 180-189

  Zhao, Yuhan ^a   Yu, Haiyang ^a   Hu, Wenwei ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

E3 ubiquitin ligase; gene regulation; MDM2; p53

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

ALTERNATIVE RNA SPLICING; BIOLOGICAL MODEL; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MDM2; METABOLISM; NEOPLASM; REVIEW;

E3 UBIQUITIN LIGASE; GENE REGULATION; MDM2; P53;

ALTERNATIVE SPLICING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897710994     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt147     Document Type: Review

References (119)

1. Cahilly-Snyder L, Yang-Feng T, Francke U and George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987, 13: 235-244.
2. Fakharzadeh SS, Trusko SP and George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991, 10: 1565-1569.
3. Roth J, Dobbelstein M, Freedman DA, Shenk T and Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17: 554-564.
4. Zhang Y and Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16: 369-377.
5. Lindstrom MS, Jin A, Deisenroth C, White Wolf G and Zhang Y. Cancer-Associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 2007, 27: 1056-1068.
6. Boddy MN, Freemont PS and Borden KL. The p53-Associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem Sci 1994, 19: 198-199.
7. Honda R, Tanaka H and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997, 420: 25-27.
8. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N and Prives C. The Mdm2 RING domain C-Terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 2007, 26: 90-101.
9. Thrower JS, Hoffman L, Rechsteiner M and Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000, 19: 94-102.
10. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323-331.
11. Lane DP. Cancer. p53, guardian of the genome. Nature 1992, 358: 15-16.
12. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R and Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302: 1972-1975.
13. Momand J, Zambetti GP, Olson DC, George D and Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69: 1237-1245.
14. Chen J, Marechal V and Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993, 13: 4107-4114.
15. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362: 857-860.
16. Takagi M, Absalon MJ, McLure KG and Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005, 123: 49-63.
17. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB and Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell 2008, 32: 180-189.
18. Montes de Oca Luna R, Wagner DS and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378: 203-206.
19. Momand J, Jung D, Wilczynski S and Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998, 26: 3453-3459.
20. Jones SN, Hancock AR, Vogel H, Donehower LA and Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998, 95: 15608-15612.
21. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR and Livingston DM. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375: 694-698.
22. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X and Lang JY, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008, 10: 138-148.
23. Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S and Nawaz Z, et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 2009, 284: 13987-14000.
24. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z and Broglio K, et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006, 26: 7269-7282.
25. Huart AS, MacLaine NJ, Meek DW and Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009, 284: 32384-32394.
26. Gu L, Zhu N, Zhang H, Durden DL, Feng Y and Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009, 15: 363-375.
27. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC and Bargonetti J, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119: 591-602.
28. Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996, 2: 912-917.
29. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y and Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998, 58: 609-613.
30. Perry ME, Piette J, Zawadzki JA, Harvey D and Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993, 90: 11623-11627.
31. Wu X, Bayle JH, Olson D and Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7: 1126-1132.
32. Barak Y, Juven T, Haffner R and Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12: 461-468.
33. Mendrysa SM and Perry ME. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol 2000, 20: 2023-2030.
34. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C and Santilli G, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003, 3: 145-160.
35. Jackson MW and Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 2000, 20: 1001-1007.
36. Biderman L, Manley JL and Prives C. Mdm2 and MdmX as regulators of gene expression. Genes Cancer 2012, 3: 264-273.
37. Biderman L, Poyurovsky MV, Assia Y, Manley JL and Prives C. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol Cell Biol 2012, 32: 1214-1225.
38. Zhao BX, Chen HZ, Lei NZ, Li GD, Zhao WX, Zhan YY and Liu B, et al. p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J 2006, 25: 5703-5715.
39. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ and Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study. Proc Natl Acad Sci USA 2000, 97: 11250-11255.
40. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB and Alon U. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004, 36: 147-150.
41. Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A and Lahav G. p53 dynamics control cell fate. Science 2012, 336: 1440-1444.
42. Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintas-Cardama A and Hamir AN, et al. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 2013, 27: 1857-1867.
43. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A and Shohet JM. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005, 102: 731-736.
44. Zhang X, Zhang Z, Cheng J, Li M, Wang W, Xu W and Wang H, et al. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem 2012, 287: 30468-30476.
45. Zhou JX, Lee CH, Qi CF, Wang H, Naghashfar Z, Abbasi S and Morse HC, III. IFN regulatory factor 8 regulates MDM2 in germinal center B cells. J Immunol 2009, 183: 3188-3194.
46. Chang CJ, Freeman DJ and Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 2004, 279: 29841-29848.
47. Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C and Levine AJ. Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007, 104: 16633-16638.
48. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H and Bartel F, et al. MDM2 SNP309 accelerates tumor formation in a genderspecific and hormone-dependent manner. Cancer Res 2006, 66: 5104-5110.
49. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD and Easton DF, et al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 2009, 11: R89.
50. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H and Guo Y, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 2011, 19: 273-282.
51. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S and Press MF. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001, 61: 3212-3219.
52. Bartel F, Taylor AC, Taubert H and Harris LC. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 2001, 12: 451-457.
53. Harris LC. MDM2 splice variants and their therapeutic implications. Curr Cancer Drug Targets 2005, 5: 21-26.
54. Chandler DS, Singh RK, Caldwell LC, Bitler JL and Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 2006, 66: 9502-9508.
55. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C and Lowe SW. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003, 63: 5703-5706.
56. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK and Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001, 20: 4041-4049.
57. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ and Roussel MF. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 2002, 62: 1222-1230.
58. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M and Rotter V, et al. Mutant p53 protein, master regulator of human malignancies: A report on the Fifth Mutant p53 Workshop. Cell Death Differ 2012, 19: 180-183.
59. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R and Barsotti A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148: 244-258.
60. Muller PA and Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013, 15: 2-8.
61. Zheng T, Wang J, Zhao Y, Zhang C, Lin M, Wang X and Yu H, et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun 2013, 4: 2996, doi:10.1038/ncomms3996.
62. Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M and Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS ONE 2013, 8: e77643.
63. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG and Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013, 32: 61-69.
64. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ and Kim T, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012, 109: 5316-5321.
65. Xiao J, Lin H, Luo X and Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011, 30: 524-532.
66. Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S and Nosrati M, et al. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 2013, 105: 433-442.
67. Hoffman Y, Bublik DR, Pilpel Y and Oren M. miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ 2013, doi:10.1038/cdd.2013.146.
68. Sachdeva M and Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010, 2: 170-180.
69. Li Q, Zou C, Han Z, Xiao H, Wei H, Wang W and Zhang L, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett 2013, 335: 168-174.
70. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O and Moas M, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 2001, 15: 1067-1077.
71. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY and Taya Y, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999, 13: 152-157.
72. Shinozaki T, Nota A, Taya Y and Okamoto K. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene 2003, 22: 8870-8880.
73. Cheng Q, Chen L, Li Z, Lane WS and Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J 2009, 28: 3857-3867.
74. Lohrum MA, Ashcroft M, Kubbutat MH and Vousden KH. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000, 2: 179-181.
75. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V and Fahraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012, 21: 25-35.
76. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA and Oren M, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 2002, 21: 3715-3727.
77. Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Parsons JL and Dianov GL. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell 2012, 45: 801-813.
78. Hu W, Feng Z and Levine AJ. The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer 2012, 3: 199-208.
79. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010, 24: 1580-1589.
80. Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999, 13: 2658-2669.
81. Zhang Y and Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999, 3: 579-591.
82. Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999, 1: 20-26.
83. Sherr CJ. Divorcing ARF and p53: An unsettled case. Nat Rev Cancer 2006, 6: 663-673.
84. Tian X, Chen Y, Hu W and Wu M. E2F1 inhibits MDM2 expression in a p53-dependent manner. Cell Signal 2011, 23: 193-200.
85. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3: 973-982.
86. Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387: 823-827.
87. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX and Kumar S, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998, 2: 405-415.
88. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE and Vande Woude GF, et al.Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997, 94: 6048-6053.
89. Lu X, Ma O, Nguyen TA, Jones SN, Oren M and Donehower LA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007, 12: 342-354.
90. Warner JR. The economics of ribosome biosynthesis in yeast. Trends Biochem Sci 1999, 24: 437-440.
91. Daftuar L, Zhu Y, Jacq X and Prives C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE 2013, 8: e68667.
92. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER and Hill DL, et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 2007, 26: 5029-5037.
93. Miliani de Marval PL and Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2011, 2: 234-238.
94. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H and Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: A cohort study. Am J Epidemiol 2003, 157: 415-423.
95. Stommel M, Given BA and Given CW. Depression and functional status as predictors of death among cancer patients. Cancer 2002, 94: 2719-2727.
96. Chida Y, Hamer M, Wardle J and Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 2008, 5: 466-475.
97. Feng Z, Liu L, Zhang C, Zheng T, Wang J, Lin M and Zhao Y, et al. Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proc Natl Acad Sci USA 2012, 109: 7013-7018.
98. Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant Wand Towers AJ, et al. A stress response pathway regulates DNA damage through beta2-Adrenoreceptors and beta-Arrestin-1. Nature 2011, 477: 349-353.
99. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C and Costa N, et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl) 2009, 87: 1221-1239.
100. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG and Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001, 29: 92-95.
101. Badciong JC and Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002, 277: 49668-49675.
102. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M and Wahl GM. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006, 9: 273-285.
103. Linares LK, Hengstermann A, Ciechanover A, Muller S and Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003, 100: 12009-12014.
104. Linke K, Mace PD, Smith CA, Vaux DL, Silke J and Day CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008, 15: 841-848.
105. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A and Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999, 447: 5-9.
106. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ and Wright PE. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 2006, 363: 433-450.
107. Wang X, Wang J and Jiang X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 2011, 286: 23725-23734.
108. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang ZG and Zuo Y, et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 2011, 108: 12001-12006.
109. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z and Kong N, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303: 844-848.
110. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S and Nikolovska-Coleska Z, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008, 105: 3933-3938.
111. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M and Pramanik A, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10: 1321-1328.
112. Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D and Di Lello P, et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 2012, 109: 11788-11793.
113. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD and Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007, 129: 2456-2457.
114. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV and Safiran YJ, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005, 7: 547-559.
115. Roxburgh P, Hock AK, Dickens MP, Mezna M, Fischer PM and Vousden KH. Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis 2012, 33: 791-798.
116. Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C and Stockwell BR. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov 2011, 1: 312-325.
117. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT and Crowley D, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119: 847-860.
118. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA and Van Pelt CS, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008, 22: 1337-1344.
119. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM and Valentin-Vega YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119: 861-872.